← Leaderboards
Sita Kugel
Massachusetts General Hospital
$5,881,835
Attributed
$5,881,835
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $805.2K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,881,835 · 5
By mechanism
R37$2,790,021 · 1
R01$1,976,767 · 1
R00$747,000 · 1
R21$187,687 · 1
K99$180,360 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Nabeel Bardeesy$18,920,034
- Supriya K Saha$1,502,420
- Raul Mostoslavsky$11,553,356
- David Tsai Ting$4,336,400
- David B Sykes$998,320
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorNovel Therapeutic InterventionMalignant NeoplasmsNeoplastic CellMolecularCell LineLoss Of FunctionMediatingMessenger RnaProgramsPathway InteractionsDependenceProteinsGenesBindingEpigenetic ProcessMaintenanceGeneticTargeted TreatmentGenetic TranscriptionAutomobile DrivingPhenotypeCombination Drug TherapyInduction Of Apoptosis
Grant awards (18)
Exploring the epigenetic control of pancreatic cancer subtypes$402,600
R37 · FY2025 · CA · contact PI
Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma$402,600
R01 · FY2025 · CA · contact PI
Exploring the epigenetic control of pancreatic cancer subtypes$382,473
R37 · FY2024 · CA · contact PI
Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma$382,471
R01 · FY2024 · CA · contact PI
Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma$394,548
R01 · FY2023 · CA · contact PI
Exploring the epigenetic control of pancreatic cancer subtypes$394,548
R37 · FY2023 · CA · contact PI
Exploring the epigenetic control of pancreatic cancer subtypes$402,600
R37 · FY2022 · CA · contact PI
Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma$394,548
R01 · FY2022 · CA · contact PI
Exploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinoma$402,600
R01 · FY2021 · CA · contact PI
Exploring the epigenetic control of pancreatic cancer subtypes$323,537
R37 · FY2021 · CA · contact PI
Exploring the epigenetic control of pancreatic cancer subtypes$79,063
R37 · FY2021 · CA · contact PI
Exploring the epigenetic control of pancreatic cancer subtypes$402,600
R37 · FY2020 · CA · contact PI
Evaluating Novel Targeted Therapies in Cholangiocarcinoma Using Tumor Slice Cultures$187,687
R21 · FY2020 · CA · contact PI
Exploring the epigenetic control of pancreatic cancer subtypes$402,600
R37 · FY2019 · CA · contact PI
Deciphering the role of Lin28b in pancreatic cancer to guide therapeutic discovery$249,000
R00 · FY2019 · CA · contact PI
Deciphering the role of Lin28b in pancreatic cancer to guide therapeutic discovery$249,000
R00 · FY2018 · CA · contact PI
Deciphering the role of Lin28b in pancreatic cancer to guide therapeutic discovery$249,000
R00 · FY2017 · CA · contact PI
Deciphering the role of Lin28b in pancreatic cancer to guide therapeutic discovery$180,360
K99 · FY2016 · CA · contact PI